We are live on ! Find out more
TCM

TCG Crossover Management Portfolio holdings

AUM $3.5B
1-Year Est. Return 1,165.83%
This Fund
S&P 500
This Quarter Est. Return
-20.68%
1 Year Est. Return
+1,165.83%
3 Year Est. Return
+3,168.76%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$733M
AUM Growth
-$290M
Cap. Flow
-$4.65M
Cap. Flow %
-0.63%
Top 10 Hldgs %
55.3%
Holding
38
New
–
Increased
2
Reduced
3
Closed
1

Top Buys

Rank Stock Value
1
TYRA icon
Tyra Biosciences
TYRA
+$11.8M
2
AMLX icon
Amylyx Pharmaceuticals
AMLX
+$4.63M

Top Sells

Rank Stock Value
1
SLNO
Soleno Therapeutics
SLNO
+$13.4M
2
KROS icon
Keros Therapeutics
KROS
+$6.39M
3
IRON icon
Disc Medicine
IRON
+$1.21M
4
RAPT
RAPT Therapeutics
RAPT
+$55.4K

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
THRD
26
DELISTED
Third Harmonic Bio
THRD
$8.69M 1.19%
2,505,424
– –
SLN
27
Silence Therapeutics
SLN
$546M
$8.55M 1.17%
3,033,560
– –
ADVM
28
DELISTED
Adverum Biotechnologies
ADVM
$7.85M 1.07%
1,796,482
– –
VTGN icon
29
VistaGen Therapeutics
VTGN
$9.55M
$6.69M 0.91%
2,676,580
– –
JBIO
30
Jade Biosciences
JBIO
$1.2B
$5.62M 0.77%
64,023
– –
TRDA icon
31
Entrada Therapeutics
TRDA
$226M
$5.29M 0.72%
584,955
– –
MBX
32
MBX Biosciences
MBX
$2.86B
$4.8M 0.65%
650,000
– –
AVTX icon
33
Avalo Therapeutics
AVTX
$1.03B
$3.87M 0.53%
483,000
– –
KOD icon
34
Kodiak Sciences
KOD
$2.52B
$3.21M 0.44%
1,145,538
– –
NKTR icon
35
Nektar Therapeutics
NKTR
$2.39B
$2.72M 0.37%
266,667
– –
VTYX
36
DELISTED
Ventyx Biosciences
VTYX
$364K 0.05%
316,195
– –
CABA icon
37
Cabaletta Bio
CABA
$445M
$120K 0.02%
86,795
– –
KROS icon
38
Keros Therapeutics
KROS
$199M
– –
-550,000
Closed -$6.39M
1
2

Similar funds

DILIC
Dai-ichi Life Insurance Company Tokyo, Japan $3.49B AUM 27.28% 1-Year Est. Return
KCM
Kedalion Capital Management London, United Kingdom $3.48B AUM 17.74% 1-Year Est. Return
ACM
Aquatic Capital Management Chicago, Illinois $3.48B AUM 24.9% 1-Year Est. Return
BCP
BDT Capital Partners Chicago, Illinois $3.51B AUM 31.02% 1-Year Est. Return
ACA
Anchor Capital Advisors Boston, Massachusetts $3.51B AUM 16.99% 1-Year Est. Return
MSC
MUFG Securities (Canada) New York $3.48B AUM 45.13% 1-Year Est. Return
TH
TCTC Holdings Dallas, Texas $3.51B AUM 30.71% 1-Year Est. Return
PMG
Private Management Group Irvine, California $3.47B AUM 13.39% 1-Year Est. Return

TCG Crossover Management's Q1 2025 Portfolio in Review

As of Q1 2025, TCG Crossover Management held 38 positions worth $733M, down 28% from $1.02B the previous quarter. Its ten largest holdings account for 55% of the portfolio.

Trading was light in Q1 2025: portfolio turnover was 2.6%. TCG Crossover Management opened no new positions and exited 1, leaving the 38-position portfolio largely intact.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • TCG Crossover Management added most to Tyra Biosciences in Q1 2025, an estimated $11.8M increase.
  • TCG Crossover Management's biggest Q1 2025 reduction was Soleno Therapeutics, cutting an estimated $13.4M.
  • TCG Crossover Management fully exited Keros Therapeutics in Q1 2025, selling an estimated $6.39M.
  • TCG Crossover Management's ten largest holdings make up 55% of its $733M portfolio in Q1 2025.
  • TCG Crossover Management opened 0 new positions and closed 1 in Q1 2025.
  • TCG Crossover Management's portfolio value fell 28% quarter-over-quarter to $733M.

Based on TCG Crossover Management's 13F filing for Q1 2025, filed 14 May 2025.